Roche says Ocrevus drug reduces need for walking aids for MS patients

Roche said its Ocrevus treatment showed fewer patients with relapsing multiple sclerosis needed walking aids, the company said today.

There was a 35 per cent reduction in the need for a walking aid in patients with relapsing multiple sclerosis (MS) after seven and a half years of taking Ocrevus, the company said. There was also a 29 per cent reduction in the 48-week progression in primary progressive MS after eight years after starting taking the drug, it added.